Please login to the form below

Not currently logged in
Email:
Password:

Parsabiv

This page shows the latest Parsabiv news and features for those working in and with pharma, biotech and healthcare.

Amgen’s R&D chief Sean Harper retires to seek biotech post

Amgen’s R&D chief Sean Harper retires to seek biotech post

Bradway said two new products – Aimovig (erenumab) for migraine and Sensipar follow-up Parsabiv (etelcalcetide) for chronic kidney disease – had started well, and the quarter was also marked by the launch ... Parsabiv meanwhile made $73m after making

Latest news

  • NICE set to back Parsabiv for kidney disease complication NICE set to back Parsabiv for kidney disease complication

    In draft guidance, the cost-effectiveness agency is backing use of Amgen's Parsabiv (etelcalcetide) for secondary hyperparathyroidism caused by CKD in patients on haemodialysis, but only for patients who cannot ... Parsabiv was approved by the EMA last

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Amgen has finally been granted FDA approval for its Parsabiv therapy for a complication of chronic kidney disease (CKD), after being turned down by the US regulator last summer. ... to be used in clinical practice, the monthly costs of Parsabiv and

  • Amgen wins European approval for Parsabiv Amgen wins European approval for Parsabiv

    European regulators have approved Amgen's Parsabiv (etelcalcetide), licensing it for secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. ... In contrast, Parsabiv is administered as an infusion during

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    Parsabiv was hoped to equal or exceed solid earner Sensipar.  . Amgen has been dealt a blow to its late-stage pipeline by the FDA, which has declined to approve a ... In contrast, Parsabiv is administered as an infusion during dialysis, side-stepping

More from news
Approximately 4 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics